GlassScriptPhysician profile
Haifan Chen
NPI 1023113610
$10,997.56
in general payments reported to CMS, 2019-2025
17 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,975 · 2020: $521 · 2021: $1,468 · 2022: $1,877 · 2023: $1,886 · 2024: $2,084 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,156.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,453.67 | 2019-2025 | Vemlidy |
| Amgen INC. | $2,634.96 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $1,328.67 | 2021-2025 | Linzess, Qulipta, Ubrelvy |
| Novo Nordisk INC | $931.28 | 2021-2025 | Rybelsus, Ozempic, Rebinyn |
| Amarin Pharma, INC. | $677.86 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $670.23 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $433.66 | 2019-2024 | Mounjaro, Jardiance |
| Axsome Therapeutics, INC. | $387.50 | 2023-2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $124.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $103.37 | 2019 | |
| Glaxosmithkline, LLC. | $59.02 | 2023-2024 | Shingrix, Arexvy, Bexsero |
| Allergan, INC. | $52.70 | 2019 | |
| Phathom Pharmaceuticals, INC. | $51.28 | 2024 | Voquezna |
| Insmed, INC. | $31.40 | 2019 | |
| Esperion Therapeutics, INC. | $20.00 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $18.95 | 2024 | |
| Oxford Immunotec USA INC | $18.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haifan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.